相关实验视频

Updated: May 1, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

探索circSCORE在患有复发/阻断性地幔细胞淋巴瘤的患者中的预后潜力

Ruth Salim^1,2, Christian Winther Eskelund^1,2, Mats Jerkeman³

¹Department of Hematology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.

|June 26, 2025

概括

一个新的基于循环RNA的风险评分,circSCORE,显示了患有复发性/耐火性地幔细胞淋巴瘤 (MCL) 的患者的预后潜力. 这种生物标志物可以帮助预测结节和非结节组织的结果,为R/R MCL管理提供了一个有前途的工具.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

膜细胞淋巴瘤 (MCL) 是一种异质的淋巴状恶性瘤.
缺少复发性/耐火性 (R/R) MCL 的最佳预后生物标志物.
基于循环RNA的风险评分 (circSCORE) 在新诊断的MCL中显示出有前途.

研究的目的:

评估R/R MCL.中的circSCORE的预后值.
评估circSCORE在结节 (淋巴结) 和非结节 (骨髓,外周血液) 组织中的实用性.
为了确定circSCORE是否保持预后意义,当调整为已建立的标记.

主要方法:

从65个R/R MCL复发样本 (20 LN, 34 BM, 11 PB) 中提取的RNA.
计算了circSCORE,并将患者分为高风险和低风险组.
卡普兰-梅尔和考克斯回归分析用于评估生存结果 (PFS,OS).

主要成果:

高风险circSCORE与明显较低的无进展生存率 (PFS) (HR 1.99,p=0.0407) 和整体生存率 (OS) (HR 2.29,p=0.0192) 相关.
在非节点组织样本中观察到类似的趋势.
在对Ki67,MIPI和TP53突变状态进行调整后,circSCORE仍然是PFS的显著预后因素.

结论:

circSCORE在R/R MCL中显示出预后潜力.
circSCORE在骨髓和外周血液等非节点组织中应用具有前景.
在等待进一步验证之前,circSCORE可以作为R/R MCL的易于获取的生物标志物.

关键词:

在NanoString中使用.生物标志物生物标志物环RNA 环RNA 是一个环RNA.电路分数电路分数电路分数地毯细胞淋巴瘤这是一个ncRNARNA.复发/耐药性疾病的复发风险评分风险评分是什么意思

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...